Risk factors for HHV-6 reactivation (multivariate analysis)
| Risk factors . | Any HHV-6 reactivation . | Clinically relevant HHV-6 infection . | ||
|---|---|---|---|---|
| P value . | HR (ci 95%) . | P value . | HR (ci 95%) . | |
| CD3 counts >100 cell per μL | .09 | 0.55 (0.27-1.10) | .02 | 0.23 (0.07-0.81) |
| Age > 53 y | .06 | 1.47 (0.99-2.19) | .20 | 1.51 (0.81-2.82) |
| Disease (vs acute leukemia) | .16 | .14 | ||
| Lymphoma/MM | .75 | 1.08 (0.67-1.74) | .76 | 0.90 (0.44-1.82) |
| MDS/MPN | .08 | 0.59 (0.33-1.06) | .05 | 0.34 (0.12-0.98) |
| Disease status (vs CR1) | .62 | .22 | ||
| Active disease | .57 | 0.83 (0.43-1.60) | .19 | 0.48 (0.16-1.43) |
| CR > 1 | .33 | 0.78 (0.48-1.28) | .11 | 0.55 (0.27-1.43) |
| HCT-CI > 2 | .14 | 0.75 (0.51-1.10) | .41 | 0.78 (0.43-1.41) |
| Previous allo-HSCT | <.01 | 2.89 (1.49-5.60) | .68 | 1.26 (0.42-3.82) |
| MAC (vs RTC) | .12 | 1.59 (0.81-3.13) | .61 | 1.35 (0.42-4.32) |
| Donor (vs haploidentical) | .40 | .95 | ||
| MRD | .97 | 0.99 (0.53-1.83) | .57 | 1.29 (0.54-3.10) |
| MUD | .24 | 1.44 (0.78-2.66) | .78 | 1.16 (0.41-3.31) |
| CBU | .33 | 0.47 (0.10-2.14) | .33 | 0.47 (0.11-2.14) |
| PT-Cy (vs ATG) | <.01 | 2.59 (1.50-4.47) | <.01 | 3.77 (1.47-9.64) |
| Steroids | <.01 | <.01 | ||
| 1 mg/kg | <.01 | 3.64 (2.34-5.66) | <.01 | 2.74 (1.44-5.24) |
| 2 mg/kg | <.01 | 4.2 (2.29-7.70) | <.01 | 3.54 (1.31-9.53) |
| Risk factors . | Any HHV-6 reactivation . | Clinically relevant HHV-6 infection . | ||
|---|---|---|---|---|
| P value . | HR (ci 95%) . | P value . | HR (ci 95%) . | |
| CD3 counts >100 cell per μL | .09 | 0.55 (0.27-1.10) | .02 | 0.23 (0.07-0.81) |
| Age > 53 y | .06 | 1.47 (0.99-2.19) | .20 | 1.51 (0.81-2.82) |
| Disease (vs acute leukemia) | .16 | .14 | ||
| Lymphoma/MM | .75 | 1.08 (0.67-1.74) | .76 | 0.90 (0.44-1.82) |
| MDS/MPN | .08 | 0.59 (0.33-1.06) | .05 | 0.34 (0.12-0.98) |
| Disease status (vs CR1) | .62 | .22 | ||
| Active disease | .57 | 0.83 (0.43-1.60) | .19 | 0.48 (0.16-1.43) |
| CR > 1 | .33 | 0.78 (0.48-1.28) | .11 | 0.55 (0.27-1.43) |
| HCT-CI > 2 | .14 | 0.75 (0.51-1.10) | .41 | 0.78 (0.43-1.41) |
| Previous allo-HSCT | <.01 | 2.89 (1.49-5.60) | .68 | 1.26 (0.42-3.82) |
| MAC (vs RTC) | .12 | 1.59 (0.81-3.13) | .61 | 1.35 (0.42-4.32) |
| Donor (vs haploidentical) | .40 | .95 | ||
| MRD | .97 | 0.99 (0.53-1.83) | .57 | 1.29 (0.54-3.10) |
| MUD | .24 | 1.44 (0.78-2.66) | .78 | 1.16 (0.41-3.31) |
| CBU | .33 | 0.47 (0.10-2.14) | .33 | 0.47 (0.11-2.14) |
| PT-Cy (vs ATG) | <.01 | 2.59 (1.50-4.47) | <.01 | 3.77 (1.47-9.64) |
| Steroids | <.01 | <.01 | ||
| 1 mg/kg | <.01 | 3.64 (2.34-5.66) | <.01 | 2.74 (1.44-5.24) |
| 2 mg/kg | <.01 | 4.2 (2.29-7.70) | <.01 | 3.54 (1.31-9.53) |
Significant values are shown in bold.
ATG, antithymocyte globulin; CBU, cord blood unit; CR, complete remission; HCT-CI, hematopoietic cell transplant–comorbidity index; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; MRD, matched-related donor; MUD, matched-unrelated donor; RTC, reduced-toxicity conditioning.